Psoriatic Arthritis

“The differential contribution of IL-6 and IL-17 pathways to the pathogenesis of psoriatic arthritis is not fully understood,” investigators stated.

Take a few minutes to check out Rheumatology Network's top expert interviews from Q2 2022.

The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.

New research suggests patients with psoriatic arthritis were at 8 times greater risk of sexual dysfunction and patients with rheumatoid arthritis were at 10 times greater risk when compared to their counterparts without either rheumatic disease.

The use of biological DMARDs was similar across countries, but in less wealthy countries, more patients with moderate/high disease activity were not receiving biologics.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 11, 2022.

Frédéric Lavie, MD, PhD, explains the results of the data presented at EULAR evaluating guselkumab for the treatment of psoriatic arthritis.

Terence Rooney, MD, explains the innovative research methods that Janssen utilizes and the benefits of precision medicine in the treatment of psoriatic arthritis.

Terence Rooney, MD, discusses recent findings indicating that guselkumab provided patients with psoriatic arthritis with sustained improvements in health-related quality of life through 2 years.

Line Uhrenholt, MD, discusses the results of her randomized, open-label, equivalence trial study evaluating disease activity-guided tapering of biologics in patients with inflammatory arthritis.

A personal history rather than a family history of psoriasis is associated with the disease activity and severity of axial joint damage.

Nicola Luigi Bragazzi, MD, PhD, explains the importance of sex-based medicine in psoriatic arthritis and shares his advice for future studies.

Catch up on Rheumatology Network's top articles of May 2022.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 28, 2022.

Investigators conducted a meta-analysis to determine the association between psoriasis and an eventual psoriatic arthritis diagnosis.

Two phase 3 studies, BE OPTIMAL and BE COMPLETE, evaluated bimekizumab in adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders.

Clinicians give their opinions on patient-reported outcome measures regarding both initial diagnosis and management of patients with rheumatic disease.

Data from 2 studies evaluating adults with active psoriatic arthritis were announced today in preparation for EULAR 2022. The different population groups who received treatment were biologic-naive patients and TNF-inadequate responders.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 21, 2022.

The Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion to expand Novartis secukinumab indication to enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).

Arthur Kavanaugh, MD, discusses his recent CCR East presentations “The Immunopathogenesis of Psoriatic Arthritis and Immunologically Targeted Therapy” and “Hot Topics in Rheumatoid Arthritis.”

One-year results from the PsABio study provide evidence on factors that may impact treatment selection and decisions in clinical practice.

“Biomarkers can be used to elucidate normal and pathological processes and to measure biological response to a therapeutic intervention,” investigators stated.

In this Q&A, Gerd R. Burmester, MD, discussed the findings of his study that evaluated the exposure to ixekizumab, outcomes and medical history of patients with active psoriatic arthritis (PsA) who experienced adverse events.

Jeffrey Stark, MD, discusses the latest bimekizumab and certolizumab pegol data presented at the 2022 American Academy of Dermatology annual meeting.